{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'responsibilities of the DMC are to ensure the patients welfare as well as', 'to evaluate and review safety and other applicable data throughout the', 'course of the study and make appropriate recommendations to the', 'Sponsor regarding the conduct of the clinical trial. The specific', 'responsibilities of the DMC will be described in the DMC charter.', 'Adjudication Committee:', 'Yes', 'No', 'Property of the Sanofi Group - strictly confidential', 'Page 12', 'VV-CLIN-0254406 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '1', 'FLOW CHARTS', '1.1', 'GRAPHICAL STUDY DESIGN', 'Pediatric study duration', 'Alemtuzumab', 'Alemtuzumab', 'DMTs', 'Screening', '(M-4)', 'M0', 'M4', 'M8', 'M12', 'M24', 'M60', 'MRI', 'Cognition', 'Period 1', 'Period 2', 'Primary MRI read out', 'Safety Monitoring', 'Phase', 'EOS', 'Screening', 'Prior DMT', 'Alemtuzumab Treatment Phase', 'EOTP', 'Period', 'Phase', '(0 to 28 days)', 'Abbreviations: DMT: disease modifying therapy; EOS: end of study; EOTP: end of treatment phase; M: month(s); MRI: magnetic resonance imaging.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0254406 5', 'Page 13']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '1.2', 'STUDY FLOW CHART', '1.2.1 Schedule of events Part 1 (Year 1)', 'Table 1 - Schedule of events in Year 1', 'DMT Phase', 'Alemtuzumab treatment phase', 'Unscheduled', 'visits', 'Visita', 'Scrn.', 'Period 1/ Prior DMT', 'MO/', 'M1', 'M2', 'M3', 'M4', 'Period 2', 'M9', 'M10', 'M11', 'M12', 'Relapse visit', 'visitb', 'phase', 'D1U', 'Eligibility', 'D-14 to', 'M5', 'M6', 'M7', 'M8', 'confirmation', 'D-7C', 'on M-4', 'Visit number', 'V1', 'V2', 'V3', 'V4v', 'V5', 'V6', 'V7', 'V8', 'V9', 'V10', 'V11', 'V12', 'V13', 'V14', 'V15', 'V16v', 'Entry procedures', 'Informed consent & assent', 'Inclusion/exclusion criteria', 'X', 'review', 'Patient demographye', 'Medical/Surgical history', 'Prior Medication history', 'Eligibility confirmation', 'X', 'Phone', 'Xg', 'Hepatitis B/C Serology testing', 'Tuberculosis test (eg,', 'Other Serology tests as required', 'HPV/(yearly)', 'Treatment:', 'Confirm eligibility for alemtuzumab Rx', 'Alemtuzumab administration', 'Premedication administration', 'Acyclovir administration', 'Compliance', 'X', 'Concomitant medications', 'Prior DMT', 'Discontinue prior DMT', 'X', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0254406: 5.0', 'Page 14']\n\n###\n\n", "completion": "END"}